EUVIMEDEUVIMED entdecken
KommentarOpen Access · CC BY 4.0

A MRSA mystery: how PBP4 and cyclic-di-AMP join forces against β-lactam antibiotics

Taylor M Gardner iD, Melinda R Grosser iD

mBio · 2024

DOI: 10.1128/mbio.01210-24 ↗

Kurz gefasst

Kommentar in der Zeitschrift mBio, 2024. Verfasst von Taylor M Gardner und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biology, University of North Carolina Asheville, Asheville, North Carolina, USA. Hauptthemen laut MEDLINE: Methicillin-Resistant Staphylococcus aureus, beta-Lactams, Anti-Bacterial Agents, Penicillin-Binding Proteins. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: American Heart Association-American Stroke Association, American Heart Association (AHA).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The high-level resistance to next-generation β-lactams frequently found in Staphylococcus aureus isolates lacking mec , which encodes the transpeptidase PBP2a traditionally associated with methicillin-resistant Staphylococcus aureus (MRSA), has remained incompletely understood for decades. A new study by Lai et al. found that the co-occurrence of mutations in pbp4 and gdpP , which respectively cause increased PBP4-mediated cell wall crosslinking and elevated cyclic-di-AMP levels, produces synergistic β-lactam resistance rivaling that of PBP2a-producing MRSA (L.-Y. Lai, N. Satishkumar, S. Cardozo, V. Hemmadi, et al., mBio 15:e02889-23. 2024, https://doi.org/10.1128/mbio.02889-23 ). The combined mutations are sufficient to explain the high-level β-lactam resistance of some mec- lacking strains, but the mechanism of synergy remains elusive and an avenue for further research. Importantly, the authors establish that co-occurrence of these mutations leads to antibiotic therapy failure in a Caenorhabditis elegans infection model. These results underscore the need to consider this unique and novel β-lactam resistance mechanism during the clinical diagnosis of MRSA, rather than relying on mec as a diagnostic.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Methicillin-Resistant Staphylococcus aureusbeta-LactamsAnti-Bacterial AgentsPenicillin-Binding ProteinsCaenorhabditis elegansStaphylococcal InfectionsAnimalsBacterial Proteinsbeta-Lactam ResistanceMutationMicrobial Sensitivity TestsCell WallHumansCyclic AMPbeta Lactam Antibiotics

Stichwörter der Autor:innen

MRSAPBP4cyclic-di-AMPgdpPmethicillin-resistant lacking mec (MRLM)β-lactam resistance

Substanzen

beta-LactamsAnti-Bacterial AgentsPenicillin-Binding ProteinsBacterial ProteinsCyclic AMPbeta Lactam Antibiotics

Autor:innen und Institutionen

  • Department of Biology, University of North Carolina Asheville, Asheville, North Carolina, USA.

ORCID-Profile: Taylor M Gardner, Melinda R Grosser

Förderung

  • American Heart Association-American Stroke Association
  • American Heart Association (AHA)

Zitieren

APA

Gardner, T. M., & Grosser, M. R. (2024). A MRSA mystery: how PBP4 and cyclic-di-AMP join forces against β-lactam antibiotics. mBio. https://doi.org/10.1128/mbio.01210-24

Vancouver

Gardner TM, Grosser MR. A MRSA mystery: how PBP4 and cyclic-di-AMP join forces against β-lactam antibiotics. mBio. 2024. doi:10.1128/mbio.01210-24

BibTeX
@article{Gardner2024,
  author = {Gardner, Taylor M and Grosser, Melinda R},
  title = {A MRSA mystery: how PBP4 and cyclic-di-AMP join forces against β-lactam antibiotics},
  journal = {mBio},
  year = {2024},
  doi = {10.1128/mbio.01210-24}
}
Kostenlos starten →